Discover and read the best of Twitter Threads about #OW2021
Most recents (4)
1/ It is no surprise that Semaglutide is the bell of the pharmacotherapy ball. Let's review some key takeaways from the STEP trials to understand why SEMA 2.4 mg is so exciting.
*credit to Dr. Wadden. #OW2021
STEP 3
*credit to Dr. Wadden. #OW2021
STEP 3
1/ Circadian Fasting: by Dr. Chow
The theme of the day => TRE researchers have a lot to say about @ethanjweiss's research. #OW2021
The theme of the day => TRE researchers have a lot to say about @ethanjweiss's research. #OW2021
3/ Early TRE, in the absence of weight loss, elicits a more optimal metabolic response: #OW2021
⬇️ insulin
⬆️ insulin sensitivity
⬇️ hunger
⬇️ BP
‼️ But is it practical?
⬇️ insulin
⬆️ insulin sensitivity
⬇️ hunger
⬇️ BP
‼️ But is it practical?
1/ Dr. Lee Kaplan: What Does the Future of Obesity Care Look Like? #OW2021
Every time I hear Dr. Kaplan speak, I am blown away by his knowledge and perspective. He, once again, delivered a masterclass on obesity.
Point #1: We are undertreating obesity
Every time I hear Dr. Kaplan speak, I am blown away by his knowledge and perspective. He, once again, delivered a masterclass on obesity.
Point #1: We are undertreating obesity
Point #2: An active, involuntary physiological system determines body fatness at any one time. #OW2021
Point #3: All our available interventions help to readjust down the increased fat mass setpoint (in theory). #OW2021
1/ Future of Obesity Treatments? #OW2021
Meet the candidates:
1) AM833 +/- Semaglutide 2.4 mg; combo therapy resulted in 15-17% at 20 weeks with no evidence of nadir, suggesting even greater wt loss (likely >20%).
by Dr. Rubino
Meet the candidates:
1) AM833 +/- Semaglutide 2.4 mg; combo therapy resulted in 15-17% at 20 weeks with no evidence of nadir, suggesting even greater wt loss (likely >20%).
by Dr. Rubino
2/ Tirzepatide; hard to imagine a future without tirzepatide (as long as safety & tolerability remain) for the treatment of metabolic dz when >10% wt loss and -2.5% A1c are avg results. Also, >50% of participants achieved normoglycemia with most doses‼️
↪️by Dr. Frias #OW2021
↪️by Dr. Frias #OW2021
3/ Setmelanotide; MC4R agonist targets central POMC/MC4R pathway in hypothalamus. Currently reserved for congenital obesity.
➡️ 1 in 300 carry MC4R loss of fxn variant (predisposes to wt gain)
➡️ 6 in 300 carry MC4R GoF variant that protects against wt gain
↪️ by @Farooqi_Lab
➡️ 1 in 300 carry MC4R loss of fxn variant (predisposes to wt gain)
➡️ 6 in 300 carry MC4R GoF variant that protects against wt gain
↪️ by @Farooqi_Lab
